TITLE

Myelodysplastic Syndromes--Many New Drugs, Little Therapeutic Progress

AUTHOR(S)
Tefferi, Ayalew
PUB. DATE
November 2010
SOURCE
Mayo Clinic Proceedings;Nov2010, Vol. 85 Issue 11, p1042
SOURCE TYPE
Academic Journal
DOC. TYPE
Opinion
ABSTRACT
In this article, the author discusses the myelodysplastic syndromes (MDS) which constitute a form of blood cancer that primarily affects the elderly and characterized by anemia and high risk of leukemic transformation. The author is critical on the establishment of a robust Mayo Clinic health record system which published several retrospective studies including those in MDS. The author also investigated the recommendations for the use of iron chelation therapy for MDS.
ACCESSION #
55414608

 

Related Articles

  • Epigenetics of myelodysplastic syndromes. Itzykson, R; Fenaux, P // Leukemia (08876924);Mar2014, Vol. 28 Issue 3, p497 

    Myelodysplastic syndromes (MDS) are clonal diseases of the elderly characterized by chronic cytopenias, dysplasia and a variable risk of progression to acute myeloid leukemia (AML). Aberrant methylation of tumor-suppressor gene promoters has been established for many years and recently tracked...

  • Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function. Castelli, Roberto; Deliliers, Giorgio; Colombo, Riccardo; Moreo, Guido; Gallipoli, Paolo; Pantaleo, Giuseppe // Annals of Hematology;Sep2014, Vol. 93 Issue 9, p1523 

    The myelodysplastic syndromes (MDS) are a group of clonal hematopoietic disorders characterized by bone marrow failure and a risk of progression to acute myeloid leukemia (AML). Anemia affects the course of disease, quality of life (QOL), and cognitive function of MDS patients....

  • Myelodysplasia is in the niche: novel concepts and emerging therapies. Bulycheva, E; Rauner, M; Medyouf, H; Theurl, I; Bornhäuser, M; Hofbauer, L C; Platzbecker, U // Leukemia (08876924);Feb2015, Vol. 29 Issue 2, p259 

    Myelodysplastic syndromes (MDSs) represent clonal disorders mainly of the elderly that are characterized by ineffective hematopoiesis and an increased risk of transformation into acute myeloid leukemia. The pathogenesis of MDS is thought to evolve from accumulation and selection of specific...

  • Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM) Della Porta, M G; Tuechler, H; Malcovati, L; Schanz, J; Sanz, G; Garcia-Manero, G; Solé, F; Bennett, J M; Bowen, D; Fenaux, P; Dreyfus, F; Kantarjian, H; Kuendgen, A; Levis, A; Cermak, J; Fonatsch, C; Le Beau, M M; Slovak, M L; Krieger, O; Luebbert, M // Leukemia (08876924);Jul2015, Vol. 29 Issue 7, p1502 

    A risk-adapted treatment strategy is mandatory for myelodysplastic syndromes (MDS). We refined the World Health Organization (WHO)-classification-based Prognostic Scoring System (WPSS) by determining the impact of the newer clinical and cytogenetic features, and we compared its prognostic power...

  • Plasma proteome changes associated with refractory anemia and refractory anemia with ringed sideroblasts in patients with myelodysplastic syndrome. Májek, Pavel; Riedelová-Reicheltová, Zuzana; Suttnar, Jiří; Pečánková, Klára; Čermák, Jaroslav; Dyr, Jan E. // Proteome Science;2013, Vol. 11 Issue 1, Special section p1 

    Background: Refractory anemia and refractory anemia with ringed sideroblasts are two myelodysplastic syndrome (MDS) subgroups linked with anemia. MDS is a group of heterogeneous oncohematological bone marrow disorders characterized by ineffective hematopoiesis, blood cytopenias, and progression...

  • Miyelodisplastik Sendromlara Kısa Bir Bakış Literatürün Derlemesi. Çıkrıkçıoğlu, Mehmet Ali; Soysal, Pınar; Erkal, Hafize; Tanrıverdi, Özgür // Medical Bulletin of Haseki / Haseki Tip Bulteni;Jun2011, Vol. 49 Issue 2, p47 

    The myelodysplastic syndrome (MDS) is a clonal stem cell disorder characterized by ineffective blood cell production and dysplasia. The most important clinical findings are anemia, leucopenia and trombocytopenia or their combinations. The MDS patients could have chronic asymptomatic cytopenias...

  • Anemia associated with physical decline in older adults.  // Geriatrics;Sep2003, Vol. 58 Issue 9, p13 

    Reports on the decline in anemia associated with physical decline in older adults in the United States, according to the Established Populations for Epidemiologic Studies of the Elderly study. Finding that neglecting aggressive treatment of anemia can hasten human decline, debility and even death.

  • Anemia in the Elderly.  // American Family Physician;10/1/2000, Vol. 62 Issue 7, p1565 

    Anemia should not be accepted as an inevitable consequence of aging. A cause is found in approximately 80 percent of elderly patients. The most common causes of anemia in the elderly are chronic disease and iron deficiency. Vitamin B12 deficiency, folate deficiency, gastrointestinal bleeding and...

  • Myelodysplastic Syndromes in Jordan: a study form a large center. Abdel, Wreikat R.; AL-Haliq, Abdel R.; Khasawneh, Rame; Al-Momani, Asim; Aladily, Tariq N. // International Journal of Biological & Medical Research;May2012, Vol. 3 Issue 3, p1525 

    Purpose: Study general data about myelodysplastic syndrome (MDS) and understanding the disease pattern in Jordan. Patients And Methods: A retrospective analysis was conducted on 134 patients, with MDS at King Hussein Medical Center, Amman, Jordan, From May2000 to May 2005 period. Recent World...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics